期刊
EXPERT REVIEW OF VACCINES
卷 13, 期 12, 页码 1489-1500出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.951335
关键词
efficacy; gp120; HIV vaccine; neutralizing antibodies; nonneutralizing antibodies; RV144; V1V2 loop
类别
资金
- US Army Medical Research and Materiel Command (USAMRMC) [DAMD17-98-2-7007]
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Although the second variable loop (V2) of the HIV-1 gp120 envelope glycoprotein shows substantial sequence diversity between strains, its functional importance imposes critical conservation of structure, and within particular microdomains, of sequence. V2 influences HIV-1 viral entry by contributing to trimer stabilization and co-receptor binding. It is one of 4 key domains targeted by the broadly neutralizing antibodies that arise during HIV-1 infection. HIV-1 uses V1V2 sequence variation and glycosylation to escape neutralizing antibody. In the Thai Phase III HIV-1 vaccine trial, RV144, vaccine-induced IgG against V1V2 inversely correlated with the risk of HIV-1 acquisition, and HIV-1 strains infecting RV144 vaccine recipients differed from those infecting placebo recipients in the V2 domain. Similarly, non-human primate challenge studies demonstrated an inverse correlation between vaccine-induced anti-V2 responses and simian immunodeficiency virus acquisition. We hypothesize that increased magnitude, frequency and duration of vaccine-induced anti-V2 antibody responses should improve efficacy afforded by pox-protein prime-boost HIV vaccine strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据